trending Market Intelligence /marketintelligence/en/news-insights/trending/b8mjhlfsmzqafb8rgmimda2 content esgSubNav
In This List

MeiraGTx adds gene therapy program with Vector Neurosciences acquisition

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


MeiraGTx adds gene therapy program with Vector Neurosciences acquisition

MeiraGTx Holdings plc has acquired privately held Vector Neurosciences Inc. in an all-stock transaction.

The acquisition adds a mid-stage gene therapy program to MeriaGTx's portfolio dubbed adeno-associated virus encoding glutamic acid decarboxylase for the treatment of Parkinson's disease. In a phase 2 clinical trial, the therapy has shown promising results when compared to placebo.

"This strategic acquisition gives us an exciting mid-stage product candidate with promising, sham-controlled clinical data and expands our portfolio of potential therapies for neurodegenerative diseases," said MeiraGTx President and CEO Alexandria Forbes.

Financial details of the acquisition were not disclosed.